dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.439341 | 877564a8d3ba4818b2855455933ed884 | (a) Coronal proton-density-weighted MRI depicting medial meniscal boundary in line with the tibial plateau and no signs of extrusion of the meniscal body (arrows). The root of the posterior horn of the medial meniscus appears thinned but without evidence of a definite tear. (b) Weight-bearing CT arthrography (WBCTa) demonstrates substantial extrusion of the medial meniscus beyond the tibial plateau (arrow). Weight-bearing imaging also reveals a complete tear of the root of the posterior tibial attachment of the medial meniscus with a wide gap (double headed arrow). WBCTa added clinical value by visualizing the cause of the patient’s persistent pain and informed the patient’s care plan. | PMC9806406 | 10.1177_1759720X221146621-fig4.jpg |
0.465246 | 879b9f0388474dd0aeca7db43f8f409e | Decision tree in the overall population. | PMC9806428 | 10.1177_17588359221141760-fig1.jpg |
0.415016 | 0df7a09a2a5549fab0065221bd70479c | Tornado diagram summarizing changes in the ICER of genomic stratification
(ODX) versus clinical stratification strategies for
overall population.ICER, incremental cost-effectiveness ratio; ODX, Oncotype DX | PMC9806428 | 10.1177_17588359221141760-fig2.jpg |
0.399847 | bc842eb6fd74403abce1bba539ee632e | ICER scatterplot per CT spared in the overall population.ICER, incremental cost-effectiveness ratio; CT, chemotherapy. | PMC9806428 | 10.1177_17588359221141760-fig3.jpg |
0.541687 | 7ab69a2722cf4f4091502567881a9f22 | Cost-effectiveness acceptability curve in the overall population. | PMC9806428 | 10.1177_17588359221141760-fig4.jpg |
0.446466 | 14ae17aa0e724c9aa6903de43f5f257a | Decision tree in high clinical risk population. | PMC9806428 | 10.1177_17588359221141760-fig5.jpg |
0.428305 | 1da91f255cf94c2fbc65fc1e98ef4a57 | Tornado diagram summarizing changes in the ICER of genomic stratification
(ODX) versus clinical stratification strategies for
high clinical risk population.ICER, incremental cost-effectiveness ratio; ODX, Oncotype DX. | PMC9806428 | 10.1177_17588359221141760-fig6.jpg |
0.516196 | 4b15087dfb124fed95958ad7c376271a | ICER scatterplot per CT spared in the high clinical risk population.ICER, incremental cost-effectiveness ratio; CT, chemotherapy. | PMC9806428 | 10.1177_17588359221141760-fig7.jpg |
0.481161 | 947cb8e6767a4be29d61c1a5a4cb19a0 | Study design | PMC9806812 | 13223_2022_753_Fig1_HTML.jpg |
0.505685 | 44b23db5262f484b82d779af12b4b1aa | Plasma levels of IL-4 (A) and IFN-γ (B) in probiotic and placebo groups before and after intervention in patients with asthma. Bars represent the mean ± SEM. *: p<0.05 | PMC9806812 | 13223_2022_753_Fig2_HTML.jpg |
0.495057 | 4cba1fb179bb47289566d08646f591f0 | The gene expression of miRNA-16 (A), miRNA-21 (B), miRNA-126 (C), miRNA-133b (D), miRNA-146a (E) and miRNA-155 (F) in the probiotic and placebo groups before and after intervention in patients with asthma. Bars represent the mean ± SEM. *: p<0.05 | PMC9806812 | 13223_2022_753_Fig3_HTML.jpg |
0.401624 | dcb718cfda334851b1a06c3f134425c4 | The correlation between miR-16 and FEV/FVC (A); miR-133 and miR-21 (B); and miR-126 and miR-155 (C) in patients with asthma. Data was analyzed by Spearman's rank correlation test. Scatter plot curve showed a negative correlation between miR-16 and FEV/FVC ratio (r=−0.38, p=0.02). A significant positive correlation between miR-133 and miR-21; and between miR-126 and miR-155 was shown in the plasma of patients with asthma (r=0.50, p=0.002) and (r=0.62, p=0.01), respectively | PMC9806812 | 13223_2022_753_Fig4_HTML.jpg |
0.414078 | 9d5521a0999143e1b70850d1561f4397 | An oral examination shows a soft-tissue mass of the right maxilla. The central part of the mass is depressed and demonstrates inflammation with necrosis. Stitches are seen in the incisional biopsy sites. | PMC9807789 | isd-52-415-g001.jpg |
0.408717 | a151d7184a6b47e8a3b63196e2e05c58 | Panoramic radiography reveals an aggressive soft tissue mass shadow with severe bone resorption involving the entire right maxilla. Dispersed bone particles are observed in the mass. | PMC9807789 | isd-52-415-g002.jpg |
0.43339 | c15233a532de4c9dbc2798dffda73dcb | Contrast-enhanced axial (A and B) and coronal computed tomographic images (C and D) show a heterogeneous mass occupying the right maxilla. A and C. Enhancement is observed in the central inflamed area and the periphery of the mass (black solid arrows). B and D. Residual bone remnants are observed along the border (black hollow arrows). | PMC9807789 | isd-52-415-g003.jpg |
0.435196 | f12d9ba946934897b1ebcb4c4f252390 | A. Gross surgical specimen shows a smooth mass surface, except for the central inflamed area. B. The sectioned specimen shows a yellowish-white homogeneous cut surface (black solid arrow). | PMC9807789 | isd-52-415-g004.jpg |
0.371336 | 1c07ae220fb34598a06ea629235a65a9 | A histopathological examination reveals strands of odontogenic epithelium (black solid arrows) in the fibro-collagenous matrix and myxoid connective tissue stroma (A. B. Hematoxylin and eosin stain, ×40 magnification). | PMC9807789 | isd-52-415-g005.jpg |
0.449261 | 71bec4af9110413380ac0be092ae6d35 | Panoramic radiograph (A) and coronal and axial cone-beam computed tomographic images (B and C, respectively) taken 3 years after surgery show a postoperative defect, but no abnormal findings suggestive of recurrence. | PMC9807789 | isd-52-415-g006.jpg |
0.425354 | a6cbe19c4bf4473cadd03bcfd38871a8 | Optic disc pit on OCT at initial visit. OCT scan of the optic nerve head of the left eye before surgery shows an optic disc pit with associated serous retinal detachment. | PMC9808207 | cop-2022-0013-0003-527050_f1.jpg |
0.419788 | d0d5a62371524845a08b6969c003cee1 | Retinal reattachment and resolution of macular edema on OCT 18 months after surgery. OCT showed retinal reattachment and restored foveal contour. | PMC9808207 | cop-2022-0013-0003-527050_f2.jpg |
0.473848 | 103c575192de43b295551e0c855d55b5 | Nerve optic disc on OCT 18 months after surgery showed the absence of retinal detachment. Eighteen months after surgery, OCT revealed the tamponated optic nerve disc. | PMC9808207 | cop-2022-0013-0003-527050_f3.jpg |
0.47694 | abfaf2264e094bfca4eb69a49bc4f945 | Principle of data collection and HFDI identification in the study. Data are collected through the ‘Kenko’ application completion by patients. Patients could have filled the first version of the app or the second version that included auto-completion and with or without the supervision of a health care professional. The risk of CYP-mediated drug interaction is automatically assessed according to previous published work.13 CYP, cytochrome P-450; HFDI, herbs and food-drug interaction; HFDS, herb, food and dietary supplements. aHDFS: regular intakes of herb, CYP-interacting food or dietary supplements. bHFDI: herb or food–drug interaction; evaluation based on Gougis et al.13cAccording to literature review. | PMC9808458 | gr1.jpg |
0.37732 | 2b10a6a0e55247b69c4095cfad7493fe | Treemap plot of the 148 HFDSs reported among the 95 patients of the study. Green tea and licorice could have been used as a phytotherapy (intake of herb/root extract) or as food (infusion or roots) through the specific food questionnaire. Phytotherapies are represented in green, food in olive green and dietary supplements in blue. HFDS, herbs, food and dietary supplements. | PMC9808458 | gr2.jpg |
0.449446 | 05416d1224de4c7685d08c50e21fffa6 | Flowchart of systematic search. | PMC9809339 | jcav14p0174g001.jpg |
0.428299 | 137e9b7ff6434f1ea8dae3a1bf4b15a1 | Forest plots of sensitivity for CEM (A) and breast MRI (B) with pooled values, and the I2 values. | PMC9809339 | jcav14p0174g002.jpg |
0.451348 | 5f6a23a2b92140b8b43a46b1abb26892 | Forest plots of specificity for CEM (A) and breast MRI (B) with pooled values, and the I2 values. | PMC9809339 | jcav14p0174g003.jpg |
0.425301 | e0098025845247c0b69f55454c63b69d | Forest plots of diagnostic odds ratio (DOR) for CEM (A) and breast MRI (B) with pooled values, and I2 values. | PMC9809339 | jcav14p0174g004.jpg |
0.452272 | ef7a42b1a0ae4d54b260faae99eba153 | Hierarchical sROC curves of CEM (black line) and breast MRI (black dotted line). The summary points of pooled sensitivity with pooled specificity for CEM and breast MRI are shown with the black circle and black triangle, respectively. | PMC9809339 | jcav14p0174g005.jpg |
0.496492 | 14d5c1cf326d4149bc662f8cca60ab23 | IDEN algorithm and gene pair-based drug repurposing.(A) Flowchart of the DCA method. (B) Flowchart of the DEA method. (C) Comparison of three IDENs. (D) Gene pair-based drug repurposing. | PMC9810203 | pcbi.1010744.g001.jpg |
0.394335 | e07d3cc02be44ccea0a73e7581136a22 | Overview of MMI-, HMI- and MHCI-related gene pairs and genes.(A-B) Number of gene pairs and genes identified by the IDEN framework. (C-D) Number of gene pairs and genes identified by the DCA method. (E-F) Number of gene pairs and genes identified by the DEA method. (G-I) Comparison of gene pairs identified by the DCA and DEA methods. (J-L) Comparison of genes identified by the DCA and DEA methods. | PMC9810203 | pcbi.1010744.g002.jpg |
0.404873 | 3d9b28b91d984593a39d1d7c7bd0b38d | Advantage and confidence of IDEN framework.(A) Expression change of identified genes. (B) Expression change of genes identified by the DCA and DEA methods. (C) Enrichment of genes identified by the DCA and DEA methods in the important gene sets. F, B and V denote human targets for fungi, bacteria and viruses, respectively, and E, H and I denote essential genes, housekeeping genes and inflammatory genes, respectively. (D) Enrichment of the subclasses of IDEN-G in the important gene sets. (E) Clustering analysis of disease and healthy samples. The rows denote disease-related genes (red: up-regulated and blue: down-regulated) and the columns denote samples. *** P<0.001, ** 0.001≤ P<0.01 and * 0.01≤ P<0.05. | PMC9810203 | pcbi.1010744.g003.jpg |
0.492878 | 2927ba97397444a085d3a67901157f75 | Evolutionary and expression features of disease-related genes.(A) dN/dS ratio. (B) Protein age. (C) Number of homologous genes. (D) Proportion of phosphorylated sites. (E) Proportion of ubiquitinated sites. (F) Proportion of acetylated sites. (G) Proportion of methylated sites. (H) Expression level of detected genes (GSE37250). (I) Expression level of detected genes (GSE39940). *** P<0.001, ** 0.001≤ P<0.01 and * 0.01≤ P<0.05. | PMC9810203 | pcbi.1010744.g004.jpg |
0.416901 | 0d24243ba86146058359a6b33b5bb7e4 | Network topology features of disease-related genes.(A) Degree centrality. (B) Closeness centrality. (C) Betweenness centrality. (D) Shortest path length. (E) MIR measure. *** P<0.001, ** 0.001≤ P<0.01 and * 0.01≤ P<0.05. | PMC9810203 | pcbi.1010744.g005.jpg |
0.485307 | a279722ef12e4ec6bfcd886350e0d027 | Expression correlations of disease-related gene pairs.(A) Absolute PCC values of specific gene pairs. (B) Absolute PCC values of gene pairs shared by two statuses. (C) Absolute PCC values of common gene pairs. (D) Network of common gene pairs. If the absolute PCC values are consistently greater than (or less than) 0.5 in different groups, the expression correlation of a gene pair is considered to be approximately equal. *** P<0.001, ** 0.001≤ P<0.01 and * 0.01≤ P<0.05. | PMC9810203 | pcbi.1010744.g006.jpg |
0.439271 | ee7ea47d27df450091a49de7159ae58e | KEGG pathway analysis of disease-related genes.(A) MMI-G. (B) HMI-G. (C) MHCI-G. (D) Common-G. | PMC9810203 | pcbi.1010744.g007.jpg |
0.413634 | 845b467250ed475285e091a15a7c6025 | Disease-related genes and gene pairs in NF-κB signaling pathway.(A) Disease-related genes. (B) Disease-related gene pairs. | PMC9810203 | pcbi.1010744.g008.jpg |
0.416141 | 3443c5a8d84240fe92b877ba805bb330 | Analysis of hub genes in different subnetworks.(A) Hub genes in Common-P. (B) Hub genes in HMI-MMI-SP. (C) Hub genes in MMI-MHCI-SP. (D) Hub genes in HMI-MHCI-SP. (E) Hub genes in HMI-SP. (F) Hub genes in MMI-SP. (G) Hub genes in MHCI-SP. (H-J) Expression levels of hub genes in the disease and healthy states. | PMC9810203 | pcbi.1010744.g009.jpg |
0.455266 | 47b7a6b404c44606a2dfb9ca927d3a81 | Comparison of our proximity measures and existing network-based drug repurposing methods.(A-C) Performance of different methods on known HIV drugs. (D-F) Performance of different methods on known TB drugs. Evaluation measures include the AUC for identifying known drugs, rankings of known drugs and other drugs, and numbers of known drugs appearing in the top K drugs. These algorithms include our gene pair-based distance measures (distance1, distance2 and distance3), disease gene-based distance measures (Guney’s distance and Zhou’s distance), graph kernel methods (commute time, diffusion, p-step, regularized Laplacian, inverse cosine and avgRank), and diffusion state distance methods (DSD). | PMC9810203 | pcbi.1010744.g010.jpg |
0.405649 | 2ed09160d3a84f38b22df55e8a62212b | Drug-target-PPI associations for MMI.(A) Relationship between anti-MMI drug candidates and MMI-associated PPIs. Top 10 PPIs with the highest number of shortest links to drug targets are shown (one PPI may correspond to multiple targets). (B) Closest PPIs regulated by azithromycin. (C) Closest PPIs regulated by ciprofloxacin, moxifloxacin, ofloxacin and sparfloxacin. (D) Closest PPIs regulated by imatinib. (E) Closest PPIs regulated by trimethoprim. | PMC9810203 | pcbi.1010744.g011.jpg |
0.404452 | a4bbcf5307da49c4961351ea719c7902 | Frequency distribution of life satisfaction for the sample. Life satisfaction is measured on a 5-point scale, ranging from 1 (very unsatisfied) to 5 (very unsatisfied). Data source: China Family Panel Studies 2010, 2012, and 2014. | PMC9811203 | fpsyg-13-1024875-g001.jpg |
0.474505 | 7214cdc52596423dabfdf33c7739bff3 | The region of common support between treated and untreated groups. | PMC9811203 | fpsyg-13-1024875-g002.jpg |
0.396908 | d7bc02407ebb486088dd83101cfb0225 | Objective response stratified by PNI value. (A) Pre-PNI and (B) post-PNI. CR, complete response; PD, progressive disease; PNI, prognostic nutritional index; PR, partial response; SD, stable disease. | PMC9811626 | ol-25-02-13635-g00.jpg |
0.406802 | b04f338f7f3442d9ae725ac46beb0915 | Kaplan-Meier curves for (A) overall survival and (B) progression-free survival from the initiation of pembrolizumab treatment for all patients. | PMC9811626 | ol-25-02-13635-g01.jpg |
0.515791 | be19e85f55074663ae4831d9bd2c0c31 | Kaplan-Meier curves for (A) overall survival and (B) progression-free survival stratified by pretreatment PNI values. The cutoff value of PNI was 36. PNI, prognostic nutritional index. | PMC9811626 | ol-25-02-13635-g02.jpg |
0.498197 | 7852119d304f479d8f18bfd5a1a4b2fd | Kaplan-Meier curves for (A) overall survival and (B) progression-free survival stratified by posttreatment PNI values within 2 months after the induction of pembrolizumab therapy. The cutoff value of PNI was 40. PNI, prognostic nutritional index. | PMC9811626 | ol-25-02-13635-g03.jpg |
0.40421 | cde9d0abb5b24d9888fd0f88e55e0433 | Historical context of this study.Major socio-political events and the corresponding timeframes of burials in the analyzed cemeteries. | PMC9812304 | pone.0279546.g001.jpg |
0.432424 | 4f55d620e4db499187b80cbc1e9103a6 | Location of the studied rural and urban cemeteries.Squares indicate urban contexts, while triangles represent rural areas. The demographic analysis for each site is reported in the pie charts, which show a high variability in the percentage of non-adult individuals in each context [54, 57, 59, 60]; (Malve, original data). ♂ = adult males; ♀ = adult females; non-adults = individuals under 17 years of age; Unknown = adult individuals for whom sex estimation was not possible. | PMC9812304 | pone.0279546.g002.jpg |
0.49907 | 3de6926f7105445190ae6da1c6c18aec | Carbon and nitrogen stable isotope values of the samples colored by the cemeteries used in this study.The urban and rural distributions are separated in the boxplots. The values of local fauna are added as references (Aguraiuja-Lätti, original data; Malve, original data). The ellipses are drawn with 95% confidence intervals, and the outliers related to the urban and rural samples were determined using the IQR criterion. | PMC9812304 | pone.0279546.g003.jpg |
0.479973 | e8739205036040d29884ce3bc7610b8a | Carbon and nitrogen stable isotope values of the samples colored corresponding to the cemeteries used in this study, plotted with the urban and rural mean adult values (including both males and females).(A) Scatter plot of the fetuses, perinates I, perinates II, and neonates. (B) Scatter plot of the infants and older children. The ID codes of the outliers and individuals with anomalous values discussed in the text are included. | PMC9812304 | pone.0279546.g004.jpg |
0.442538 | c9aefc0ef6744533a36a90427cc5ac9d | Boxplot of the δ15N values of rural and urban children.The blue color indicates urban individuals, while the pink color indicates rural individuals. The non-adult values were plotted against the mean δ15N values of the urban and rural female individuals at the age of 20–35 and 35–50 years, indicated in the graph with the blue and pink dotted and dashed lines. The children in the 1–7 and 7–15 categories were further divided into smaller 2-years groups to provide higher resolution to the data. Statistical outliers have been determined for each age group according to the IQR criterion. | PMC9812304 | pone.0279546.g005.jpg |
0.427375 | 7a0cca0f3f5b4a0c96370b3b3ea56612 | Sagittal proton density MRI images of the left TMJ. a Closed mouth position showing the posterior band of the disc is anterior to the 12:30 position in relation to the superior aspect of the condyle indicating anterior disc displacement. b Open mouth position showing the disc returning to the normal position suggesting ADDWR | PMC9813084 | 11282_2022_617_Fig1_HTML.jpg |
0.459377 | 2b376fdb6cf34211a86df001102b099c | Standardized orientation of CBCT MPR views | PMC9813084 | 11282_2022_617_Fig2_HTML.jpg |
0.469848 | 19854fee2fc64ff3b17a09e7c68a9f11 | Condyle shapes, a Convex, b Round, c Flattened, d Angled | PMC9813084 | 11282_2022_617_Fig3_HTML.jpg |
0.472447 | 770926aa8cf7455fad240755612114fe | CBCT corrected sagittal view of the condyle showing measurement of the anterior (3.02 mm) and posterior joint space (1.27 mm) to determine the condyle position | PMC9813084 | 11282_2022_617_Fig4_HTML.jpg |
0.508123 | a2d5002ca7654e1bbbd2d9d6a6f7674c | Corrected coronal view showing the mediolateral condyle width along the axial plane passing through the condyle and the condyle height along the sagittal plane as the perpendicular distance from the top of the condyle till the axial plane | PMC9813084 | 11282_2022_617_Fig5_HTML.jpg |
0.472206 | 60eddb5838ea4701bd7e1cf8f47f80ba | Corrected sagittal view showing the anteroposterior condyle dimension | PMC9813084 | 11282_2022_617_Fig6_HTML.jpg |
0.381044 | d2b58557b5d04924b82d10b9b9f64b14 | Flow diagram for microplastic extraction from salt samples | PMC9813175 | 11356_2022_22101_Fig1_HTML.jpg |
0.442195 | f6bf6aa230dd4480a1a31c1e2663b861 | Microscopic and fluorescence images of isolated microplastics. a Clear fragment from Himalayan pink salt (salt G). b Fluorescence image of MPs in salt G. c Clear fragment from sea salt (salt C). d Fluorescent image of MPs in salt C. e Microscopic image of yellow fibre from black salt (salt B). f Fluorescent image of MPs in salt B. All the images were captured at 40 × magnification | PMC9813175 | 11356_2022_22101_Fig2_HTML.jpg |
0.411206 | b541195bea4649b5b2d42ef3f987cd99 | Colour profile of MP a fragments and b fibres observed from salt samples (in 180 g of salt sample) | PMC9813175 | 11356_2022_22101_Fig3_HTML.jpg |
0.371227 | 61594e6ee61141a982a01cd41e5bf4d1 | Comparison of fragments and fibres in different commercial salt samples (in 180 g of salt sample). Adjusted p value: ****p < 0.0001, **p = 0.0078. Fibre number in salt A was statistically significant to fibre number in salts C, D, E, and F (p < 0.0001). Fibres in salt G were statistically significant with fibres in salts C, D, E, and F (p < 0.0001). Similarly, fibre number in salt B was statistically significant with fibres in salts C, D, E, and F (p < 0.0001). Finally, fibres in salt A were statistically significant with fibre number in salt B (p = 0.0078) | PMC9813175 | 11356_2022_22101_Fig4_HTML.jpg |
0.409363 | 44d72bc615e54cf98c1e6357bd8bf115 | SEM images of isolated particles from salt samples. a, c, d Fibres and b fragments. e–h depict the surface adhered particles on a–d. D is the width of fibres (i.e. distance between P1 to P2) | PMC9813175 | 11356_2022_22101_Fig5_HTML.jpg |
0.385992 | e2c0416c6a6e4206b42d8f9d4d1ea0c6 | a Polymer chemistry of isolated microplastics from commercial salts. b Proportion of identified polymer types | PMC9813175 | 11356_2022_22101_Fig6_HTML.jpg |
0.397773 | 12ebfb45211c4e8c8ea4bc2319b81259 | ATR-FTIR spectral data of the microplastics found in the salt samples | PMC9813175 | 11356_2022_22101_Fig7_HTML.jpg |
0.480363 | 5c57266fa17143e2837a2b47be4cad78 | Activated BCR signaling or its oncogenic mimics activate SRC family kinases such as LYN, resulting in phosphorylation of CD19-Y482/513 and IFITM3-Y20. Phosphorylated tyrosine residues on CD19, which provide docking sites for the SH2 domains of the PI3K regulatory subunit p85, facilitates localization and activation of PI3K to the lipid raft on plasma membrane. Transiently synthesized PIP3 by the PI3K catalytic subunit p110 stably accumulated by IFITM3 at the BCR signalosome. IFITM3, therefore, stabilizes the BCR signalosome, supports PIP3-mediated recruitment of downstream effector molecules such as BTK and ATK, enhances BCR signaling or BCR-mimicking oncogenic signaling. The effect of the amphipathic helix of IFITM3-mediated cholesterol accumulation at lipid raft on BCR signaling has not yet been investigated. | PMC9813432 | bmb-55-12-602-f1.jpg |
0.432156 | 647cdb1a5c0d44f2a2f8a51c8b99ee83 | Lytic activity of Abp95 phage on A. baumannnii sensitive strain AB2013-95. (A) Abp95 plaques formed in a double-layer agar plate after infection of the AB2013-95 host; (B) Graphic of measured OD600 values of AB2013-95 bacterial culture during the time with (+) or without (−) Abp95; (C)–(E) Abp95 cause lysis in a bacterial culture after incubation. (Phage was added to the left tube and equal PBS was added to the right tube, (D): 4 h after adding phage, (E): 6 h after adding phage). | PMC9813454 | 41598_2022_26696_Fig1_HTML.jpg |
0.458159 | 786faab857d947609f080c0826517c93 | One-Step growth curve (A), thermal stability of Abp95 (B) and Phage Abp95 adsorption onto AB2013-95 (C). | PMC9813454 | 41598_2022_26696_Fig2_HTML.jpg |
0.474959 | 408ca63733774d7d86e513a3a41e6cbb | Electron microscopy of Abp95. (A) The morphology of Abp95 under TEM magnified by 0.5 million times (A) and 1 million times (B). | PMC9813454 | 41598_2022_26696_Fig3_HTML.jpg |
0.445054 | d3c12508a185426d86423a58db710ef5 | Major phage proteins and restriction endonuclease mapping of Abp95. (A) lane 1, SDS-PAGE of purified phage particles; lane 2, protein molecular weight marker. (B) Lane 1, DNA molecular weight markers Lambda DNA digested with HindIII; lane 2 and 3, Abp95 genomic DNA digested by XhoI and NheI, respectively; lane 4, Abp95 nondigested DNA. (the gel is cropped). | PMC9813454 | 41598_2022_26696_Fig4_HTML.jpg |
0.387079 | c6ee94bb5d8f4ea98651491f9b71c03e | Characterization of 58 sensitive A. baumannii strains. (A) Sources of the 58 strains. wd (wound surface), sp (sputa), ca (catheter), bl (bloodstream), ps (purulent secretion) and ti (tissue); (B) STs identified among 58 strains. | PMC9813454 | 41598_2022_26696_Fig5_HTML.jpg |
0.453114 | d8899e1b568f4186ac89d419fd4f1088 | Wound size in infected mice treated with Abp95. Wound sizes were measured 1, 3, and 7 days after infection and are shown as mean ± standard deviation. There was no statistical difference between the control group and the phage treatment group. | PMC9813454 | 41598_2022_26696_Fig6_HTML.jpg |
0.423792 | 090b4271566347e8847d61b99fd517d4 | Flowchart of the results of the literature search. | PMC9813495 | fmed-09-960960-g001.jpg |
0.399916 | 1cb9510e195b4bf895875ee7c8b4a5d2 | The number of studies on EAAM in a given year reported in absolute terms. Studies exploring a mixed intervention of massages and other application types were counted as massage studies. | PMC9813495 | fmed-09-960960-g002.jpg |
0.441447 | 2e6a0e6aaf21425eb097dbff62bd9a77 | Studies on EAAM per level of evidence category reported in absolute terms. | PMC9813495 | fmed-09-960960-g003.jpg |
0.457967 | 1bf2f3955efc4ac3b9ec4bcb9387594b | N‑heterocyclic carbene complexes serve as molecular gyroscopes.Binuclear Cu(I) and Au(I) complexes of 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene ligands bridged by deuterated pyrazine provide a scaffold for 2-fold rotational motion in luminescent amphidynamic crystals. Adapted with permission from J. Am. Chem. Soc. 139, 18115– 18121. Copyright (2021) American Chemical Society. | PMC9814036 | 42004_2021_458_Fig1_HTML.jpg |
0.466023 | bf6017f6e5d64a0cbdb8004c478cc423 | Identification of SfMCT inhibitors.A Screening for L-lactate transport inhibitors using a transport inhibition assay (final inhibitor concentrations are indicated). Full names and molecular structures of the used compounds are given in Supplementary Fig. 1. For compounds highlighted by a star, Ki values were determined. Residual uptake in the presence of competitor is normalized with respect to control samples without competitor (control). B–J
Ki determination of selected inhibitors with displayed structures. The determined Ki values and the 95% confidence intervals are indicated in the corresponding panels. Data are represented as mean ± SEM from three to five independent experiments, each in triplicate. If not visible, error bars are smaller than symbols. Individual data points are shown as open circles. | PMC9814091 | 42004_2021_564_Fig1_HTML.jpg |
0.417208 | 88a4bed259f94073b3ae6650b15103c0 | SfMCT ligand binding site.A Overall structure of SfMCT in the outward-open conformation viewed in the plane of the membrane with indicated binding site residues (cyan) and surface representation. B–F Binding mechanism of 1OHN2C, N2C, 3PP, 2M3PP, and TSA to SfMCT. Corresponding omit maps are shown in Supplementary Fig. 4. Residues within a distance of 4 Å from the bound compounds are displayed as ball-and-stick models and highlighted in cyan. Pink spheres indicate the centers of benzene rings of aromatic residues and inhibitors, which are involved in π–π stacking interactions. Water molecules are indicated by labeled red spheres. The role of the second water molecule (2) is shown in Supplementary Fig. 7. The different rotamer conformation of L28 in the case of TSA binding is indicated by a star in (F). Distances are given in Ångström (Å). G, H The orientation between the guanidinium plane of R280 and the carboxylate-groups of bound inhibitors can be quantified by measuring the angle ψ between the Nε–Cζ and Cx–Cy bonds as well as the angle θ between the guanidinium (cyan) and the carboxylate (gray) planes. The following angles were measured: 1OHN2C
ψ = 15°, θ = 15°; N2C
ψ = 16°, θ = 20°; 3PP
ψ = 17°, θ = 31°; 2M3PP
ψ = 11°, θ = 18°; TSA
ψ = 69°, θ = 16°. PDB IDs of displayed structures are 6ZGR (1OHN2C), 6ZGS (3PP), 6ZGT (N2C), 6ZGU (2M3PP) and 6G9X (TSA). | PMC9814091 | 42004_2021_564_Fig2_HTML.jpg |
0.436092 | 0817fafec26344968968830b374a8340 | Hydrophobic interactions involved in ligand binding.Ligands A
1OHN2C, B
N2C, C
3PP, and D
2M3PP as determined by structural analysis21. Hydrophobic residues within a distance of 4 Å from the bound compounds are displayed as ball-and-stick models and highlighted in cyan. The centers of benzene rings of aromatic residues and inhibitors, which are involved in π–π stacking interactions, are indicated by pink spheres. Distances are given in Ångström (Å). E–H Surface representations of the inhibitor binding site region. Bound compounds are displayed as ball-and-stick models. A cavity between TMs 7 and 10 is indicated by a black curved line and a star. PDB IDs of displayed structures are 6ZGR (1OHN2C), 6ZGS (3PP), 6ZGT (N2C), and 6ZGU (2M3PP). | PMC9814091 | 42004_2021_564_Fig3_HTML.jpg |
0.454031 | ea374d44d6b64b949605b1a74ebba383 | Flowchart corresponding to the identification, screening, eligibility, and included criteria of this study. | PMC9814600 | 41598_2022_26583_Fig1_HTML.jpg |
0.532145 | 95629549b5b144b286a146898f2853db | (A) Effects of strength training on systolic blood pressure in overall hypertensive individuals. (B) Effects of strength training on diastolic blood pressure in general hypertensive individuals. | PMC9814600 | 41598_2022_26583_Fig2_HTML.jpg |
0.459196 | a081626d6d754467bbf86dd1daa4d741 | (A) Effects of strength training on systolic blood pressure in hypertensive individuals aged 18–50 and 51–70 years old. (B) Effects of strength training on diastolic blood pressure in hypertensive individuals with 18–50 and 51–70 years. | PMC9814600 | 41598_2022_26583_Fig3_HTML.jpg |
0.460692 | 8f4aa7ece16143d0b474a6770d46f842 | (A) Effects of strength training on systolic blood pressure in hypertensive individuals with less than 60% load intensity, 60% moderate Borg scale, and more than 60% of load intensity. (B) Effects of strength training on diastolic blood pressure in hypertensive individuals with less than 60% of load intensity, 60% moderate Borg scale, and more than 60% of load intensity. | PMC9814600 | 41598_2022_26583_Fig4_HTML.jpg |
0.411723 | 6506fbe0fed7493caec3a8af1d6fba5c | (A) Effects of strength training on systolic blood pressure in hypertensive individuals with 2 and 3 days a week of training frequency. (B) Effects of strength training on diastolic blood pressure in hypertensive individuals with 2 and 3 days a week of training frequency. | PMC9814600 | 41598_2022_26583_Fig5_HTML.jpg |
0.445688 | 0d01eface9004d16bb664104d0f90bbf | (A) Effects of strength training on systolic blood pressure in hypertensive individuals with 8 to 10, 12, and 14 to 48 weeks of training duration. (B) Effects of strength training on diastolic blood pressure in hypertensive individuals with 8 to 10, 12, and 14 to 48 weeks of training duration. | PMC9814600 | 41598_2022_26583_Fig6_HTML.jpg |
0.432906 | fbc336699f8b4956951f869cfe836897 | (A) Funnel plot for the meta-analysis of strength training such as treatment of hypertension. Egger’s test (P = 0.01729) shows a significant publication bias. Beck et al.26 and Moraes et al.33 are the biggest outliers. (B) Risk of bias graph. | PMC9814600 | 41598_2022_26583_Fig7_HTML.jpg |
0.475673 | a0e0829f445648f6b8fe5bd194faaddc | Role of finger millet bio-active molecule induced gut microbes in alleviation of diabetes; butyrate producers Faecalibacterium, Roseburia, and Eubacterium play a crucial role in reducing systemic inflammation by maintaining the gut barrier function to avoid the gut invasion by pathogenic microbes and toxins. Mucus degrading Akkermansia, participates in glucose-homeostasis by means of Amuc_1100 protein and regulates the blood glucose and lowers the gut inflammatory load by releasing propionate. Probiotics (Bifidobacterium and Lactobacillus) also improves the toxin level by modulating the gut community, i.e., by lowering the various possible opportunistic pathogen, and simultaneously enhancing the beneficial microbes. | PMC9815516 | fnut-09-1056445-g001.jpg |
0.442949 | 9d81fbed6b214026bace975e8bb3bb19 | Study Flow Diagram. Consort Diagram showing that 41 potential participants were screened and 30 were enrolled, out of which 15 per group (COC or Depo). | PMC9816169 | 41598_2022_24215_Fig1_HTML.jpg |
0.438085 | 6b1f5f6bc48a4ee7ab4b739b93037fce | (A) Levonorgestrel (LNG) concentrations measured by LCMS/MS method in serum and urine samples were collected on days-1 and 3 of the COC treatment. No individuals showed detectable LNG in serum or urine at baseline (Pre) but all showed an increase at 6 h post ingestion on both days (day-1 and 3). Only eight of 15 participants had detectable levels at all three time points post baseline. Six participants had LNG levels below the level of quantification at the trough timepoint (24 h post dose 2), three of whom also had undetectable levels 6 h after their first dose. (B) Levonorgestrel (LNG) concentrations measured by Enzyme
Immuno assay (EIA) method in urine samples collected on day-1 and 3 of the COC treatment. No individuals
showed detectable LNG in serum or urine at baseline (Pre) and showed detectable levels at all time points post
ingestion on both days (day-1 and 3). (C) Medroxyprogesterone (MPA) concentrations measured by LC–MS/MS method in serum and urine samples collected on day 0 (Baseline) and 21 and 60 days after depo injection. Four individuals had detectable MPA in serum prior to receiving their injection, two of whom also had detectable MPA in urine. The two women with undetectable urine MPA but detectable serum MPA had levels below that required for contraceptive efficacy (< 0.2 ng/mL). One individual with undetectable serum MPA, had detectable urine MPA, with the level in the urine slightly above the serum threshold level (< 0.2 ng/mL). We detected MPA in serum and urine of all participants at 21- and 60-days post injection. | PMC9816169 | 41598_2022_24215_Fig2_HTML.jpg |
0.41329 | 9947e1e638a54690a0f685e75f596d12 | (A–C) A bi-clustering heatmap showing the visual expression profile of the top differentially expressed genes sorted by their adjusted p-value by plotting their log2 transformed expression values in samples (generated by using the Wald test). (A) shows the pre- versus D21 comparison where we observed 10 differentially expressed genes, out of which nine were upregulated and one was downregulated. (B) shows pre-versus D60 comparison, we saw five differentially expressed genes; one was downregulated and four were upregulated. (C) shows the last comparison between D21 versus D60, there were a total of 50 differentially expressed genes out of which 32 were downregulated and 18 were upregulated. | PMC9816169 | 41598_2022_24215_Fig3_HTML.jpg |
0.45959 | a31219edfe7b43449cb4bcb6ff21acab | (A–C) Volcano plots to visualize the expression profile of the top differentially expressed genes sorted by their adjusted p-value by plotting their log2 transformed expression values. Downregulated DEGs are noted in red and upregulated DEGs are noted in blue. | PMC9816169 | 41598_2022_24215_Fig4_HTML.jpg |
0.409565 | d5224e5b763642658963d4c0ac1ff4aa | Competitive Ki screening. (A) CETSA EC50 analysis of AR in intact CWR22Pc-R1-AD1 cells treated with DHT, DHT and darolutamide, or DMSO control. Normalized AlphaLISA signals from intact cell samples heated to 46 °C after incubation with a 7-step dilution series of darolutamide (N = 4; n = 8) in the presence of serially diluted DHT. (B) Schild plot showing the fold change in agonist CETSA EC50 at the indicated darolutamide concentration, where A´ is the darolutamide concentration normalized to the corresponding EC50 value in the absence of darolutamide (A). | PMC9817687 | cancers-15-00002-g001.jpg |
0.419572 | c47a4de21cfb4ababbfe778c58170a3f | Comparison of expressed protein-coding genes and proteins detected in VCaP cells across all treatment conditions. For proteomic data analysis, proteins with signals in three replicates of at least one condition (N = 7427) were selected. (A) Euler diagram showing the overlap between the expressed protein-coding genes and corresponding proteins at both time points. (B) Histogram showing average expression (TPM) of genes detected only in RNA-seq (blue) or in both RNA-seq and proteomic data (green). (C) Scatter plot of average mRNA and protein expression. The top five most abundant genes and proteins are marked in blue and green, respectively. (D) Pie chart showing the functional classification of the most abundant genes (top 100 based on average expression across all treatment conditions). (E) Pie chart showing the functional classification of the most abundant proteins (top 100 based on average expression across all treatment conditions). | PMC9817687 | cancers-15-00002-g002.jpg |
0.452349 | da61d6dff58b4f2483af052f10a63d66 | (A) Principal component analysis of transcriptomic and proteomic data generated from VCaP cells treated with DMSO, R1881 or R1881 and darolutamide for the indicated time. The percent of explained variance is indicated on the axes. (B) Proportion of variance explained by the first ten principal components in proteomic and transcriptomic data. (C) Top hallmark gene sets enriched among mRNAs and proteins that are down- or up-regulated at least twofold upon darolutamide and R1881 treatment, compared to R1881 treatment only. Stars (*) indicate FDR < 0.25. | PMC9817687 | cancers-15-00002-g003.jpg |
0.431919 | 8ba215dee4b34ea894c035d996b7a4af | (A) Heatmap plots of mRNA (left side) and protein (right side) levels of AR activity signature genes following treatment of VCaP cells with DMSO, R1881, or R1881 and darolutamide for the indicated times. (B) Scatterplots of Log2 fold changes in mRNA and protein abundance upon R1881 and darolutamide treatment compared to R1881 treatment alone. Gene expression after 8 h and protein level after 14 h of treatment was determined as early time point (left side). Gene expression after 22 h and protein level after 28 h of treatment was determined as late time point (right side). Genes with differential magnitude of response on the mRNA and protein levels are indicated in black, a few selected androgen targets are highlighted. | PMC9817687 | cancers-15-00002-g004.jpg |
0.393015 | 2e5d097441cd47ee980145eb11dd5fa7 | Gene and protein expression changes upon androgen, or androgen and darolutamide treatment, relative to the corresponding DMSO control which was set to 1 (grey horizontal dotted line). Blue bars indicate expression of genes measured by RNA-seq, green bars indicate levels of proteins measured by tandem mass spectrometry. (A) Examples of genes with discordant changes in mRNA and protein levels. (B) Examples of genes with similar responses at the mRNA and protein levels. Stars indicate the false discovery rate (FDR) for comparison of the indicated condition to the corresponding DMSO control: *** p < 0.0001, ** p < 0.001, * p < 0.01. | PMC9817687 | cancers-15-00002-g005.jpg |
0.452513 | 8070a3cb17ca43fbbcdb1e8069cdf061 | Determination of AR peaks and AR-mediated loops around selected gene regions in VCaP cells treated with DMSO, androgen, or androgen and darolutamide. (A) AR HiChIP and ChIP-seq results for genes with divergent regulation of RNA and protein levels. (B) AR HiChIP and ChIP-seq results for genes with parallel regulation of RNA and protein levels. Loop intensities are reflected by the thickness of the lines. | PMC9817687 | cancers-15-00002-g006a.jpg |
0.504354 | 254506257418416c8286ae807edd7be7 | Overview of the mechanisms involved in probiotics’ antigenotoxic activity. | PMC9818275 | cancers-15-00190-g001.jpg |
0.469003 | 078936b692e14ef78a0222448738fbc0 | Expansion of NanoLC-EI-MS chromatogram of FFAs in Chia seed oil. | PMC9818636 | foods-12-00023-g001.jpg |
0.409309 | 37517b495ab14dd0a3b46bbb4d3ab6c4 | Expansion of NARP-HPLC-APCI(+)-qMS chromatogram of TAGs in Chia seed oil. | PMC9818636 | foods-12-00023-g002.jpg |
0.416258 | 6b352b0da366483fbfbd98725cefaa87 | RP-UHPLC-APCI(+)-qMS analysis of phospholipids in Chia seed oil. | PMC9818636 | foods-12-00023-g003.jpg |
0.412803 | d9bba670d8e74460b583c83de7eeac02 | Expansion of the RP-LC-ESI(−)-qMS chromatogram of polyphenols in Chia seed oil. | PMC9818636 | foods-12-00023-g004.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.